Use of immunomodulatory therapy (other than interferon) for the treatment of chronic hepatitis B virus infection

Journal of Gastroenterology and Hepatology (Australia)

Volumn 15, Issue SUPPL. MAY, 2000, Pages

  Lau, George K K ^a  

^a QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; HEPATITIS B VACCINE; INTERFERON; INTERLEUKIN 12; THYMOSIN ALPHA1;

ANTIGEN ANTIBODY COMPLEX; CLINICAL TRIAL; CONFERENCE PAPER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B; HUMAN; IMMUNOMODULATION; LIVER TOXICITY; PRIORITY JOURNAL; SEROCONVERSION; TREATMENT OUTCOME;

EID: 0033918386     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.2000.02102.x     Document Type: Conference Paper

References (63)

1. Maynard JE, Kane MA, Alter MJ, Hadler SC. Control of hepatitis B by immunization: Global perspective. In: Zuckerman AJ ed. Viral Hepatitis and Liver Disease. New York: Alan R Liss Inc., 1988: 967-9.
2. Lau GKK, Wu PC, Lai CL. Natural history of chronic HBV infection. HK Med. J. 1997; 3: 283-8.
3. Lok ASF. Treatment of chronic hepatitis B. J. Viral Hepatitis 1994; 1: 105-24.
4. Lau GKK, Carman WF, Locarnini S, Okuda K, Winterleukinliams R, Lam SK. Treatment of chronic HBV infection: an Asia-Pacific perspective. J. Gastroenterol. Hepatol. 1999; 14: 3-12.
5. Lok ASF, Wu PC, Lai CL et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 1992; 102: 2091-7.
6. Lok ASF, Chung HT, Liu VWS, Ma OCK. Long-term follow-up of chronic hepatitis B treated with interferon alpha. Gastroenterology 1993; 105: 1833-8.
7. Fontana RJ, Lok ASF. Combination therapy for chronic hepatitis B. Hepatology 1997; 26: 234-7.
8. Liaw YF, Lai CL, Leung NWY et al. Two-year lamivudine therapy in chronic hepatitis B infection: Results of a placebo controlled multicenter study in Asia. Gastroenterology 1988; 114: A1289.
9. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999; 30: 567-72.
10. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu. Rev. Immunol. 1995; 13: 29-60.
11. Mason AL, Xu L, Guo L, Kuhns M, Perrillo RP. Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen. Hepatology 1998; 276: 1736-42.
12. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nature Med. 1996; 1104-8.
13. Sztein MB, Serrate SA, Goldstein AL. Modulation of interleukin 2 receptor expression on normal human lymphocytes by thymic hormones. Proc. Natl Acad. Sci. USA 1986; 83: 6107-11.
14. Serrate SA, Schulof RS, Leonidas L, Goldstein AL, Sztein MB. Modulation of human natural killer cell cytotoxic activity, lymphokine production, and interleukin 2 receptor expression by thymic hormones. J. Immunol. 1987; 139: 2338-43.
15. Mutchnick MG, Lindsay KL, Schiff ER et al. Thymosin alpha-1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study. J. Viral Hepatitis 1999; 6: 397-403.
16. Andreone P, Cursaro C, Gramenzi A et al. A randomized controlled trial of thymosin-alpha-1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody- and hepatitis B virus DNA-positive chronic hepatitis B. Hepatology 1996; 24: 774-7.
17. Chien RN, LiawYF, Chen TC, Yeh CT, Sheen IS. Efficacy of thymosin α1 in patients with chronic hepatitis B: a randomised, controlled trial. Hepatology 1998; 27: 1383-7.
18. Lu ZM, Gao J, Yao GB et al. and China Thymosin Study Group. A comparative trial of thymosin alone and thymosin plus interferon in the treatment of Chinese patients with chronic hepatitis B (CHB). Hepatology 1997; 26: 426A.
19. Lau GKK, ST Yuen, A Kwok, ST Lai, W Lim, Lam SK. Six months follow-up on 26 weeks trial of Thymosin α1 plus Famcilcovir in the treatment of Chinese immune tolerant adult patients with chronic hepatitis B. Gastroenterology 1999; 116: A339.
20. Vitiello A, Ishioka G, Grey HM et al. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxicT lymphocyte response in humans. J. Clin. Invest. 1995; 95: 341-9.
21. Livingston BD, Crimi C, Grey H et al. The hepatitis B virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection. J. Immunol. 1997; 159: 1383-92.
22. Heathcote J, McHutchison K, Benner T et al. CY-1899: A therapeutic vaccine for chronic hepatitis B. Hepatology 1996; 24: 283A.
23. Livingston BD, Alexander J, Crimi C et al. Altered helper T lymphocyte function associated with chronic hepatitis B virus infection and its role in response to therapeutic vaccination in humans. J. Immunol. 1999; 162: 3088-95.
24. Penna A, Fowler P, Bertoletti A et al. Hepatitis B virus (HBV)-specific cytotoxic T-cell CTL response in humans: characterization of HLA class II-restricted CTLs that recognize endogenously synthesized HBV envelope antigens. J. Virol. 1992; 66: 1193-8.
25. Celis E, Ou D, Otvos L. Recognition of hepatitis B surface antigen by human T lymphocytes: Proliferation and cytotoxic responses to a major antigenic determinant defined by synthetic peptides. J. Immunol. 1988; 140: 1808-15.
26. Mancini M, Hadchouel M, Tiollais P, Pourcel C, Michel ML. Induction of anti-hepatitis B surface antigen HBsAg antibodies in HBsAg producing transgenic mice: a possible way of circumventing 'nonresponse' to HBsAg. J. Med. Virol. 1993; 39: 67-74.
27. Mancini M, Hadchouel M, Davis HL, Whalen RG, Tiollais P, Michel ML. DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state. Proc. Natl Acad. Sci. USA 1996; 93: 12496-501.
28. Pol S, Driss F, Carnot F, Michel ML, Berthelot P, Brechot C. Efficacy of immunotherapy with vaccination against hepatitis B virus on virus B multiplication. C. R. Acad. Sci. III 993; 316: 688-91.
29. Pol S, Driss F, Michel ML, Nalpas B, Berthelot P, Brechot C. Specific vaccine therapy in chronic hepatitis B infection. Lancet 1994; 344: 342.
30. Couillin I, Pol S, Mancini M, Driss F, Brechet C, Tiollais P, Michel ML. Specific vaccine therapy in chronic hepatitis B: induction ofT cell proliferative responses specific for envelope antigens. J. Infect. Dis. 1999; 180: 15-26.
31. Wen YM, Xiong SD, Zhang W. Solid matrix-antibody-antigen complex can clear viraemia and antigenaemia in persistent duck hepatitis B virus infection. J. Gen. Virol. 1994; 75: 335-9.
32. Wen YM, Zhang W, XuYY, Luo YF, Li PY Elimination of immune tolerance to hepatitis virus in an animal model. Chin. Med. J. 1992; 105: 199-203.
33. Davis HL, McCluskie MJ, Gerin JL, Purcell RH. DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines. Proc. Natl. Acad. Sci. USA. 1996; 93: 7213-18.
34. Chow YH, Huang WL, Chi WK, Chu YD, Tao MH. Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2. J. Virol. 1997; 71: 169-78.
35. Schirmbeck R, BohmW, Ando K, Chisari FV, Reimann J. Nucleic acid vaccination primes hepatitis B virus surface antigen-specific cytotoxic T lymphocytes in non-responder mice. J. Virol. 1995; 69: 5929-34.
36. Davis HL, Schirmberk R, Reimann J et al. DNA-mediated immunization in mice induces a potent MHC class-I restricted cytotoxic T lymphocyte response to the hepatitis B envelope protein. Hum. Gene Ther. 1995; 6: 1447-56.
37. Ulmer JB, Donnelly JJ, Parker SE et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259: 1745-9.
38. Mancini M, Hadchouel M, Tiollais P, Michel ML. Regulation of hepatitis B virus mRNA expression in a hepatitis B surface antigen transgenic mouse model by interferon-gamma-secreting T cells after DNA-based immunization. J. Immunol. 1998; 161: 5564-70.
39. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol. 1995; 13: 251-76.
40. Gately MK. Interleukin-12: potential clinical applications in the treatment of chronic viral hepatitis. J. Viral Hepatitis 1997; 4(Suppl. 1): 33-9.
41. Ahuja SS, Mummidi S, Malech HL, Ahuja SK. Human dendritic cell DC)-based anti-infective therapy: engineering DCs to secrete functional interferon-gamma and interleukin-12. J. Immunol. 1998; 161: 868-76.
42. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-52.
43. Rossol S, Marinos G, Carucci P, Singer MV, Winterleukinliams R, Naoumov NV Interleukin-12 induction of Th1 cytokines is important for viral clearance in chronic hepatitis B. J. Clin. Invest. 1997; 99: 3025-33.
44. Niederau C, Heintges T, Lange S et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N. Engl. J. Med. 1996; 334: 1422-7.
45. Liaw YF, Chen YC, Sheen IS. Spontaneous clearance of hepatitis B surface antigen in chronic hepatitis B virus infection confers a favorable response. Hepatology 1999; 29: 296-7.
46. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: A meta-analysis. Ann. Intern. Med. 1993; 119: 312-23.
47. Lok ASF, Liang RH, Chung H. Recovery from hepatitis B (Letter). Ann. Intern. Med. 1992; 116: 957.
48. Ilan Y, Nagler A, Adler R, Tur-Kaspa R, Slavin S, Shouval D. Ablation of persistent hepatitis B by BMT from a hepatitis B immune donor. Gastroenterology 1993; 104: 1818-21.
49. Chen PM, Fan S, Liu CJ et al. Changing of hepatitis B virus markers in patients with bone marrow transplantation. Transplantation 1990; 49: 708-13.
50. Ustun C, Koc H, Karayalcin S et al. Hepatitis B virus infection in allogeneic bone marrow transplantation. Bone Marrow Transplant. 1997; 20: 289-96.
51. Reed EC, Myerson D, Corey L, Meyers JD. Allogeneic marrow transplantation in patients positive for hepatitis B surface antigen. Blood 1991; 77: 195-200.
52. Lau GKK, Lok ASF, Liang RHS et al. Clearance of HBsAg after bone marrow transplantation: role of adoptive immunity transfer. Hepatology 1997; 25: 1497-1501.
53. Lau GKK, Liang R, Lee CK, Yuen ST, Lim WL, Williams R. Clearance of persistent hepatitis B virus infection in Chinese bone marrow transplant BMT recipients from anti-HBc+/anti-HBs+ BMT donors. J. Infect. Dis. 1998; 178: 1585-91.
54. Lau GKK, Liang R, Chiu EKW, Lee CK, Lam SK. Loss of HBsAg in chronic hepatitis B carrier following high dose chemotherapy and autologous peripheral blood stem cell rescue for lymphoma. Am. J. Hematol. 1995; 50: 317-18.
55. Hess AD, Jones RJ, Morris LE et al. Autologous graft-versus-host disease: a novel approach for antitumour immunotherapy. Hum. Immunol. 1992; 34: 219-24.
56. Martin J, Bosch O, Moraleda G, Bartolome J, Quiroga JA, Carreno V. A pilot study of recombinant human granulocyte-macrophage colony-stimulating factor for the treatment of chronic hepatitis B. Hepatology 1993; 18: 775-80.
57. Korenman J, Baker B, Waggoner J et al. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann. Intern. Med. 1991; 114: 629-34.
58. Shouval D, Ilan Y. Transplantation of hepatitis B immune lymphocytes as means for adoptive transfer of immunity to hepatitis B virus. J. Hepatol. 1995; 23: 98-101.
59. Shouval D, Ilan Y Immunization against hepatitis B through adoptive transfer of immunity. Intervirology 1995; 38: 41-6.
60. Hervas-Stubbs S, Lasarte JJ, Sarobe P et al. Therapeutic vaccination of woodchucks against chronic woodchuck hepatitis virus infection. J. Hepatol. 1997; 27: 726-37.
61. Guidotti LG, Ando K, Hobbs MV et al. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc. Natl Acad. Sci. USA 1994; 91: 3764-8.
62. Caselitz M, Link H, Hein R et al. Hepatitis B associated liver failure following bone marrow transplantation. J. Hepatol. 1997; 27: 572-7.
63. Boni C, Bertoletti A, Penna A et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J. Clin. Invest. 1998; 102: 968-75.